- Tous > Medicine Access and Rational Use > Better Medicines for Children
- Tous > Medicine Access and Rational Use > Supply Management
- Mots-clés > access to maternal/RH medicines
- Mots-clés > data collection
- Mots-clés > estimating unmet needs - essential maternal health medicines
- Mots-clés > maternal, newborn, and child health commodities
- Mots-clés > needs assessment
- Mots-clés > quantification of commodities
- Mots-clés > supply management
- Mots-clés > women's health and child
(2014; 53 pages) [French]
Maheen Malik, Beth Yeager. 2013. Estimation of Unmet Medical Need for Essential Maternal Health Medicines. Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Arlington, VA: Management Sciences for Health.
Despite momentous efforts and investments made at both the global and national levels by international and local stakeholders to reduce maternal mortality, a substantial number of countries are not on target to meet Millennium Development Goal (MDG) 5. Increasing access to and use of essential commodities for maternal health have recently gained attention as key concerns of several international initiatives. The United Nations (UN) Commission on Life-Saving Commodities for Women and Children acknowledges supply and demand challenges as among the main barriers to access and use of these life-saving commodities. A basic step in improving access to these commodities is making sure they are available where and when women need them. To do so requires proper supply planning, which for various reasons has been a challenge for essential maternal medicines, such as their use for multiple indications and the lack of both morbidity and true consumption data on which to base quantification.
The purpose of this document is to present an approach that will allow national program managers and other key stakeholders to assess a country’s theoretical need for the three overlooked life-saving maternal health commodities (i.e., oxytocin, magnesium sulfate, and misoprostol) and compare this with actual procurement data...